Highly stereoselective hydrogenations-as key-steps in the total synthesis of statins

Chirality

Volumn 22, Issue 5, 2010, Pages 534-541

  Andrushko, Natalia ^a   Andrushko, Vasyl ^a   Tararov, Vitali ^a   Korostylev, Andrei ^a   König, Gerd ^b   Börner, Armin ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b ratiopharm GmbH   (Germany)

Author keywords

Asymmetric catalysis; Asymmetric hydrogenation; Atorvastatin; Drug synthesis; Enantioselectivity; Rosuvastatin; Statins; Stereoselectivity

Indexed keywords

1,3 DIOXANE DERIVATIVE; 1,3 DIOXOLANE; ACETIC ACID ETHYL ESTER; ACID ANHYDRIDE; ALCOHOL; ALDEHYDE; ATORVASTATIN; LACTONE; MALIC ACID; METHANOL; METHYLTRIPHENYLPHOSPHONIUM; PIPERAZINE; ROSUVASTATIN; SODIUM HYDROXIDE;

CATALYST; ENANTIOSELECTIVITY; ESTERIFICATION; EVAPORATION; HYDROGENATION; HYDROLYSIS; JONES OXIDATION; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RACEMIZATION; REVIEW; ROOM TEMPERATURE; SAPONIFICATION; STEREOCHEMISTRY; SYNTHESIS; VACUUM;

FLUOROBENZENES; HEPTANOIC ACIDS; HYDROGENATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; PYRROLES; STEREOISOMERISM; SULFONAMIDES;

EID: 77950791804     PISSN: 08990042     EISSN: 1520636X     Source Type: Journal    
DOI: 10.1002/chir.20782     Document Type: Review

References (43)

1. Gaw A Packard CJ Shepherd J. Statins: the HMG CoA reductase inhibitors in perspective. London: Taylor & Francis; 2004. 262 p.
2. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-1429.
3. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003;91 (5A Suppl S):11C-17C. (Pubitemid 36332150)
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582.
5. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004;291:2821-2827. (Pubitemid 38747801)
6. Cummings SR, Bauer DC. Do statins prevent both cardiovascular disease and fracture? JAMA 2000;283:3255-3257. (Pubitemid 30422045)
7. Zhou Z, Rahme E, Pilote L, Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention, Am Heart J 2006;151:273-281.
8. van der Harst P, Voors AA, van Gilst WH, Böhm M, van Veldhuisen DJ. Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 2006;3:e333-e333; literature cited therein. (Pubitemid 44338378)
9. Kaye JA, Meier CR, Walker AM, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. Brit J Cancer 2002;86:1436-1439. (Pubitemid 34548066)
10. Ray SK, Rege NN. Atorvastatin: in the management of hyperlipidae-mia. Drug Rev 2000;46:242-243.
11. Wierzbicki AS, Mikhailidis DP, Wray R, Schachter M, Cramb R, Simpson WG, Byrne CB. Statin-fibrate combination therapy for hyperlipi-daemia: a review. Curr Med Res Opin 2003;19:155-168. (Pubitemid 36612998)
12. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg ASP, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJP, Hutten BA. Statin treatment in children with familial hypercholesterolemia. Circulation 2007;116:664-668.
13. 1). In: Contemporary drug synthesis. New York: Wiley-Inter-science; 2004. p 113-124.
14. Maggon K, Best-selling human medicines 2002-2004. Drug Discov Today 2005;10:739-742.
15. Croom KF, Plosker GL. Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 2005;65:137-152.
16. Law MR, Rudnicka AR, Statin safety a systematic review. Am J Cardiol 2006;97 (suppl 8A):52C-60C.
17. Brower PL, Butler DE, Deering CF, Le TV, Millar A, Nanninga TN, Roth BD. The synthesis of (4R-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3- dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 1992;33:2279-2282.
18. Baumann KL, Butler DE, Deering CF, Mennen KE, Millar A, Nan-ninga TN, Palmer CW, Roth BD. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett 1992;33:2283-2284.
19. Rádl S, Stach J, Hajicek J. An improved synthesis of 1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis. Tetrahedron Lett 2002;43:2087-2090. (Pubitemid 34188529)
20. George S, Sudalai A. An efficient organocatalytic route to the atorvas-tatin side-chain. Tetrahedron Lett 2007;48:8544-8546. (Pubitemid 350016181)
21. Pandey PS, Rao TS. An efficient synthesis of N3,4-diphenyl-5-(4- fluorophenyl)-2-isopropyl-1H-3-pyrrolecarboxamide, a key intermediate for atorvastatin synthesis. Bioorg Med Chem Lett 2004;14: 129-131. (Pubitemid 38010207)
22. Culhane NS, Lettieri SL, Skae JR. Rosuvastatin for the treatment of hypercholesterolemia. Pharmacotherapy 2005;25:990-1000; literature cited therein.
23. Hirsch M, O'Donnell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol 2005;104:251-256. (Pubitemid 41375583)
24. Hoey S. The therapeutic benefits of rosuvastatin. Brit J Card Nurs 2008;3:482-484.
25. Quirk J, Thornton M, Kirkpatrick P. Rosuvastatin calcium. Nature Rev Drug Discov 2003;2:769-770; literature cited therein.
26. Pfefferkorn JA. Second-generation HMG-CoA reductase inhibitors. Synthesis of rosuvastatin. In: Johnson DS, Li JJ, editors. The art of drug synthesis. New Jersey: John Wiley; 2007. p 174-176; literature cited therein.
27. Casar Z, Mesar T. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof. EP1978020 A1, 2008.
28. Balanov A, Shenkar N, Niddam-Hildesheim V. Preparation of rosuvas-tatin. US Pat Appl, US2007167625 A1, 2007.
29. Radl S, Stach J, Klvana R, Jirman J. A method for the production of the hemi-calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino]pyrimidine-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid. PCT Int Appl, WO 2007000121 A1, 2007.
30. Patel DJ, Kumar R, Dwivedi SPD. Process for preparing rosuvastatin calcium. WO2007099561 A1, 2007
31. Available at: http://www.forbes.com
32. Tararov VI, Andrushko N, Andrushko V, König G, Spannenberg A, Börner A. Synthesis of the chiral side chain of statins\lactone versus lactol pathway. Eur J Org Chem 2006:5543-5550.
33. Tararov VI, König G, Börner A. Synthesis and highly stereoselective hydrogenation of the statin precursor ethyl (5S)-5,6- isopropylidene-dioxy-3-oxohexanoate. Adv Synth Catal 2006b;348:2633-2644.
34. Saito S, Hasegawa T, Inaba M, Nishida R, Fujii T, Nomizu S, Mori-wake T. Combination of borane-dimethyl sulfide complex with catalytic sodium tetrahydroborate as a selective reducing agent for á-hydroxy esters. Versatile chiral building block from (S)-(2)-malic acid. Chem Lett 1984;13:1389-1392.
35. Saito S, Ishikawa T, Kuroda A, Koga K, Moriwake T. A revised mechanism for chemoselective reduction of esters with borane-dimethyl sulfide complex and catalytic sodium tetrahydroborate directed by adjacent hydroxyl group. Tetrahedron 1992;48:4067-4086.
36. Brooks DW, Lu LDL, Masamune S, C-Acylation under Virtually Neutral Conditions. Angew Chem Int Ed Engl 1979;18:72-74.
37. Kitamura M, Tokunaga M, Ohkuma M, Noyori R. Convenient preparation of binap-ruthenium(II) complexes catalyzing asymmetric hydrogenation of functionalized ketones. Tetrahedron Lett 1991;32: 4163-4166.
38. Tararov V, Korostylev A, Börner A, Bobál P, Frantisek J, Stohandl J, Denike K, Jeker N. Process for preparing C5 products and their use for atorvastatin synthesis. EP1705175 A1, 2006.
39. Korostylev A, Andrushko V, Andrushko N, Tararov VI, König G, Börner A. Highly enantioselective hydrogenation of ethyl 5,5-di-methoxy-3-oxopentanoate and its application for the synthesis of a statin precursor. Eur J Org Chem 2008:840-846.
40. Andrushko V, Andrushko N, König G, Börner A. Highly enantioselec-tive catalytic hydrogenation of a 5-amino-3,5-dioxopentanoic ester. Tetrahedron Lett 2008;49:4836-4839.
41. Andrushko N, Andrushko V, König G, Spannenberg A, Börner A. A new approach to the total synthesis of rosuvastatin. Eur J Org Chem 2008:847-853.
42. Poupardin O, Greck C, Genêt J-P. Rapid asymmetric synthesis of highly functionalized C5 chiral synthons. Practical preparation of trans-3-hydroxy-D-proline. Synlett 1998;11:1279-1281.
43. Review of Stereochemistry, Regis Technologies; 2000, 19, www.educhimica.it/Organica/Chiralreview.pdf. Accessed August 2008. 534-541